New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
13:42 EDTHTWRHeartWare off lows after preliminary Q4 revenue tops expectations
Shares remain down 59c to $88.91 on the day.
News For HTWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2015
09:10 EDTHTWRNorthland sees HeartWare takeover as 'highly unlikely
Northland analyst Suraj Kalia believes the sympathy rally in shares of HeartWare (HTWR) after St. Jude Medical (STJ) announced the acquisition of Thoratec (THOR) could be short lived. HeartWare has already tried to sell itself to larger medical device companies over the past few years, Kalia tells investors in a research note, citing his own field work. He views a buyout of HeartWare at this stage as "highly unlikely" and feels speculation of a $102-$122 per share takeover price is based on "na´ve and unsophisticated" analysis. Kalia keeps an Underperform rating on HeartWare with a $60 price target. The maker of implantable heart pumps, following a two-day rally, closed yesterday at $88.21.
July 21, 2015
16:28 EDTHTWROn The Fly: Top stock stories for Tuesday
Subscribe for More Information
15:08 EDTHTWRThoratec reaches all-time high after report of St. Jude takeover
Subscribe for More Information
12:40 EDTHTWRSt. Jude in talks to acquire Thoratec, Bloomberg reports
St. Jude Medical (STJ) is in talks to acquire Thoratec (THOR), Bloomberg reports, citing people familiar with the situation. Talks are ongoing and could still fall apart as no deal has been reached, Bloomberg adds. Thoratec shares spiked early in today's session, but a catalyst for the move was unclear before the Bloomberg report. Shares of the medical device maker focused on advanced heart failure patients are up $9.52 to $58.33 in midday trading. Its close competitor HeartWare (HTWR) is now up $5.53 to $84.70. Shares of St. Jude are up 4 to $76.61. Reference Link
12:33 EDTHTWRThoratec jumps after Bloomberg report of St. Jude buyout talks
Subscribe for More Information
10:20 EDTHTWRCatalyst behind Thoratec spike higher unclear
The catalyst behind the spike higher in shares of Thoratec (THOR) is unclear to traders and investors. The medical device maker focused on advanced heart failure patients rose as high $62.05 in early trading and its shares remain up 11%, or $5.48, to $54.29. Some vague takeover chatter surfaced, with St. Jude Medical (STJ) as the speculated buyer, but buyout rumors are often the "go-to" reason when stocks spike. Often the moves on rumors are less substantial than Thoratec's spike today. The company's close competitor HeartWare (HTWR) is not seeing any unusual trading thus far today, falling 36c to $78.81 in early trading.
09:58 EDTHTWRThoratec jumps 14% to $55.82 in early trading
Subscribe for More Information
July 20, 2015
07:10 EDTHTWRHeartWare begins its MVAD System CE Mark international clinical trial
Subscribe for More Information
July 15, 2015
10:59 EDTHTWRHeartWare drops after analyst cuts target to $60
Shares of HeartWare are moving lower after Northland analyst Suraj Kalia cut his price target for the name to $60 from $70. The company manufactures implantable heart pumps for patients suffering from advanced heart failure. Recent sheep data for the company's MVAD Pump with new impeller design show a "flowrate profile that seems to be on a downtrend over time," Kalia told investors this morning in a research note. The incomplete data raise more questions, the analyst contends. The MVAD Pump is a continuous axial flow pump, one-third the size of HeartWare's current heart pump, HVAD, according to the company. Kalia believes the MVAD will be more "problematic in patient management" than the HVAD over the long term. The analyst has an Underperform rating on HeartWare, Northland's sell rating equivalent. Shares of medical device company are down $2.22 to $71.22 in morning trading. Its peer Thoratec (THOR) is up 16c to $46.69.
08:57 EDTHTWRLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
08:49 EDTHTWRHeartWare price target lowered to $60 from $70 at Northland
Northland lowered its price target for HeartWare to $60 saying the latest sheep study publication for the MVAD with new impeller design raises more questions. The firm believes that over the long term, MVAD will be more problematic in patient management than the HVAD. It keeps an Underperform rating on HeartWare.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use